0001209191-18-059969.txt : 20181126 0001209191-18-059969.hdr.sgml : 20181126 20181126195402 ACCESSION NUMBER: 0001209191-18-059969 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20181126 FILED AS OF DATE: 20181126 DATE AS OF CHANGE: 20181126 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Ettenberg Seth CENTRAL INDEX KEY: 0001734419 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38443 FILM NUMBER: 181201795 MAIL ADDRESS: STREET 1: C/O UNUM THERAPEUTICS INC. STREET 2: 200 CAMBRIDGE PARK DRIVE SUITE 3100 CITY: CAMBRIDGE STATE: MA ZIP: 02140 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Unum Therapeutics Inc. CENTRAL INDEX KEY: 0001622229 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 465308248 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 200 CAMBRIDGE PARK DRIVE STREET 2: SUITE 3100 CITY: CAMBRIDGE STATE: MA ZIP: 02140 BUSINESS PHONE: 617-945-5576 MAIL ADDRESS: STREET 1: 200 CAMBRIDGE PARK DRIVE STREET 2: SUITE 3100 CITY: CAMBRIDGE STATE: MA ZIP: 02140 FORMER COMPANY: FORMER CONFORMED NAME: Unum Therapeutics, Inc. DATE OF NAME CHANGE: 20141014 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2018-11-26 0 0001622229 Unum Therapeutics Inc. UMRX 0001734419 Ettenberg Seth C/O UNUM THERAPEUTICS INC. 200 CAMBRIDGE PARK DRIVE, SUITE 3100 CAMBRIDGE MA 02140 0 1 0 0 Chief Scientific Officer Common Stock 2018-11-26 4 M 0 11485 0.18 A 11485 D Common Stock 2018-11-26 4 S 0 11485 7.0043 D 0 D Stock Option (Right to Buy) 0.18 2018-11-26 4 M 0 11485 0.00 D 2025-01-28 Common Stock 11485 363600 D The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.79 to $7.41, inclusive. The reporting person undertakes to provide to Unum Therapeutics Inc., any security holder of Unum Therapeutics Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. 25% of the shares vests on September 3, 2015, and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Persons continuous service with the Issuer. /s/ Amoli Pandya, as Attorney-in-Fact 2018-11-26